Introduction {#cti21103-sec-0005}
============

Grass pollen (GP) is the most clinically important outdoor aeroallergen source involved in eliciting allergic rhinitis (AR) and asthma in sensitised patients.[1](#cti21103-bib-0001){ref-type="ref"} GP has been identified as the leading trigger of the most severe thunderstorm‐related asthma outbreak globally,[2](#cti21103-bib-0002){ref-type="ref"} including the most recent and fatal occurring in Melbourne, Australia, in 2016, with 10 related deaths.[3](#cti21103-bib-0003){ref-type="ref"}, [4](#cti21103-bib-0004){ref-type="ref"}, [5](#cti21103-bib-0005){ref-type="ref"} Both temperate and subtropical grasses are found in places with diverse climatic regions such as parts of Australia, Africa, India and America[6](#cti21103-bib-0006){ref-type="ref"} (Supplementary figure [1](#cti21103-sup-0001){ref-type="supplementary-material"}). Research has indicated differences in allergen composition and immune recognition between the pollen of grasses from different subfamilies.[7](#cti21103-bib-0007){ref-type="ref"}, [8](#cti21103-bib-0008){ref-type="ref"}, [9](#cti21103-bib-0009){ref-type="ref"} Given an increase in the global population living in subtropical climates,[10](#cti21103-bib-0010){ref-type="ref"} the competitive advantage of subtropical grasses at elevated carbon dioxide concentrations[11](#cti21103-bib-0011){ref-type="ref"} and the expansion of subtropical zones because of climate change,[12](#cti21103-bib-0012){ref-type="ref"}, [13](#cti21103-bib-0013){ref-type="ref"} subtropical grasses of Panicoideae (*Paspalum notatum* and *Sorghum halepense*) and Chloridoideae (*Cynodon dactylon*), subfamilies are likely to become more important allergen sources in the future.

Early research from southern subtropical states of the United States of America (USA) indicated that *P. notatum* GP was the most frequently positive GP amongst 429 AR patients from Louisiana and of atopic children of military personnel in Texas.[14](#cti21103-bib-0014){ref-type="ref"} In the subtropical region of Queensland (QLD), Australia, patients with AR showed higher levels of allergic sensitisation to pollen of subtropical grasses *P. notatum* and *C. dactylon* than temperate *L. perenne* by skin prick test (SPT), serum‐specific IgE[15](#cti21103-bib-0015){ref-type="ref"} and cross‐inhibition of specific IgE (spIgE) reactivity with whole GP extracts.[16](#cti21103-bib-0016){ref-type="ref"} In contrast, patients from the temperate region of Melbourne (Australia) showed higher serum spIgE reactivity with *L. perenne* GP extract and its major allergen, Lol p 1, than with *P. notatum* and *C. dactylon* GP and their group 1 allergens, Pas n 1 and Cyn d 1, respectively.[17](#cti21103-bib-0017){ref-type="ref"}

A subsequent cross‐inhibition study of AR patients from Queensland (QLD) showed that spIgE to subtropical *P. notatum*, *C. dactylon* and *S. halepense* GP was inhibited more by these subtropical GP than a mixture of five temperate GP.[18](#cti21103-bib-0018){ref-type="ref"} Elsewhere using pooled sera of five patients highly allergic to temperate GP in Minnesota, USA, Bermuda GP was unable to achieve 50% inhibition of sIgE reactivity with temperate GP *Koeleria macrantha, Dactylis glomerata*, *Festuca pratensis* or *L. perenne*. Conversely, in the same study, four orders of magnitude more than *P. pratense* GP extract were required to achieve 50% inhibition of IgE reactivity with *C. dactylon* GP.[19](#cti21103-bib-0019){ref-type="ref"} Collectively, these studies indicate that GP allergens of subtropical species have distinct immunological reactivity from temperate GP. However, research to date has not integrated clinical history with sensitisation studies of patients from diverse climates. Most cross‐inhibition studies have used small numbers of subjects or serum pools to examine relationships between GP extracts rather than major allergen components.

This study aimed to comprehensively investigate regional differences in levels of allergic sensitisation to subtropical and temperate GP in different biogeographical locations separated by thousands of kilometres. This is the first study to evaluate the variation in levels of spIgE recognition of major group 1 pollen allergens representing subtropical grasses Panicoideae (*P. notatum* and *S. halepense*) and Chloridoideae (*C. dactylon*) subfamilies, as well as temperate grasses Pooideae (*L. perenne* and *P. pratense*), using a semi‐automated microscale IgE cross‐inhibition format exemplified across four Australian regions in distinct climatic zones.

Results {#cti21103-sec-0006}
=======

A total of 330 GP‐allergic participants with AR were recruited based on clinical history and positive SPT to at least one of four GP tested (Table [1](#cti21103-tbl-0001){ref-type="table"}). The age distributions of the GP‐allergic AR group were similar to both control groups, non‐atopic (NA) participants and those with other allergies,[20](#cti21103-bib-0020){ref-type="ref"} frequently house dust mite and/or cat dander, who showed negative SPT and serum spIgE to the four GP tested (Table [1](#cti21103-tbl-0001){ref-type="table"}). There was a higher proportion (65.5%) of females in the GP‐allergic group than the NA group (44.8%) (*P* \< 0.05). The other allergy (OA) and GP‐allergic participants showed higher levels of total IgE than the NA group. Amongst the GP‐allergic group, there was no difference in gender nor total IgE between participants from each state (Table [2](#cti21103-tbl-0002){ref-type="table"}), QLD with a subtropical climate, NSW with mixed temperate and subtropical climates, and WA and SA with temperate climates (Supplementary figure [1](#cti21103-sup-0001){ref-type="supplementary-material"}).[21](#cti21103-bib-0021){ref-type="ref"} GP‐allergic participants from NSW were older than other regions and had lower level of grass pollen sensitisation (Table [2](#cti21103-tbl-0002){ref-type="table"}).

###### 

Demographics and clinical history of participants recruited in the Grass Pollen Allergy Study (GPAS)

                                                                         Non‐atopic          Other allergy                                                   Allergic rhinitis with Grass pollen allergy
  ---------------------------------------------------------------------- ------------------- --------------------------------------------------------------- ---------------------------------------------------------------
  Number                                                                 29                  54                                                              330
  Age[\[Link\]](#cti21103-note-0003){ref-type="fn"}                      45.4 (37.5--57.4)   32.6 (19.2--36.8)                                               41.2 (35.3--46.6)
  Number of females (%)[\[Link\]](#cti21103-note-0003){ref-type="fn"}    13 (44.8%)          27 (50%)                                                        216 (65.5%)[\*](#cti21103-note-0005){ref-type="fn"}
  Number with asthma (%)[\[Link\]](#cti21103-note-0003){ref-type="fn"}   1 (3.4%)            14 (25.9%)[\*](#cti21103-note-0005){ref-type="fn"}              126 (38.1%)[\*\*\*\*](#cti21103-note-0008){ref-type="fn"}
  Sum of SPT (mm)[\[Link\]](#cti21103-note-0004){ref-type="fn"}          5 (4--12)           13.5 (8--20)[\*\*\*\*](#cti21103-note-0008){ref-type="fn"}      39 (29--54)[\*\*\*\*](#cti21103-note-0008){ref-type="fn"}
  Total IgE (IQR)[\[Link\]](#cti21103-note-0004){ref-type="fn"}          31.5 (10.7--67.5)   142 (49.7--346)[\*\*\*\*](#cti21103-note-0008){ref-type="fn"}   126 (52.5--290)[\*\*\*\*](#cti21103-note-0008){ref-type="fn"}

Values expressed as medians with interquartile range in parentheses.

IQR, interquartile range; n.s., not significant; SPT, skin prick test.

Fisher\'s exact test for difference in frequencies relative to the NA group.

Kruskal--Wallis test for difference between medians between groups with Dunn\'s pairwise comparisons.

*P* ≤ 0.05.

*P* ≤ 0.0001.

John Wiley & Sons, Ltd

###### 

Age, gender, total IgE, grass pollen‐specific and allergen‐specific IgE of grass pollen allergic patients from different regions

+--------------------------------------------------------------------------+-------------------+-------------------+-------------------+-------------------+---------------------------------------------------------+
| Region                                                                   | QLD               | WA                | NSW               | SA                | Statistical differences                                 |
+==========================================================================+===================+===================+===================+===================+=========================================================+
| Number                                                                   | 138               | 73                | 39                | 80                |                                                         |
+--------------------------------------------------------------------------+-------------------+-------------------+-------------------+-------------------+---------------------------------------------------------+
| Age[\[Link\]](#cti21103-note-0011){ref-type="fn"}                        | 44 (36--51.8)     | 39 (28--49.5)     | 52 (41--66)       | 39 (30--50)       | NSW \> QLD[\*\*](#cti21103-note-0014){ref-type="fn"}    |
|                                                                          |                   |                   |                   |                   |                                                         |
|                                                                          |                   |                   |                   |                   | NSW \> WA[\*\*\*](#cti21103-note-0015){ref-type="fn"}   |
|                                                                          |                   |                   |                   |                   |                                                         |
|                                                                          |                   |                   |                   |                   | NSW \> SA[\*\*\*](#cti21103-note-0015){ref-type="fn"}   |
+--------------------------------------------------------------------------+-------------------+-------------------+-------------------+-------------------+---------------------------------------------------------+
| Number of females (%)[\[Link\]](#cti21103-note-0012){ref-type="fn"}      | 98 (71.0)         | 42 (57.5)         | 26 (66.7)         | 51 (63.0)         | n.s.                                                    |
+--------------------------------------------------------------------------+-------------------+-------------------+-------------------+-------------------+---------------------------------------------------------+
| Total IgE, kU L^−1^ [\[Link\]](#cti21103-note-0011){ref-type="fn"}       | 128.5 (73--252.8) | 154 (45.5--318.5) | 137 (62.8--302.5) | 68 (41--189)      | n.s.                                                    |
+--------------------------------------------------------------------------+-------------------+-------------------+-------------------+-------------------+---------------------------------------------------------+
| Sum of SPT to GP (mmD)[\[Link\]](#cti21103-note-0011){ref-type="fn"}     | 22 (18--27)       | 30 (22--48.8)     | 18 (9--27)        | 25 (19--34)       | WA \> NSW[\*\*\*\*](#cti21103-note-0016){ref-type="fn"} |
|                                                                          |                   |                   |                   |                   |                                                         |
|                                                                          |                   |                   |                   |                   | WA \> QLD[\*\*](#cti21103-note-0014){ref-type="fn"}     |
|                                                                          |                   |                   |                   |                   |                                                         |
|                                                                          |                   |                   |                   |                   | SA \> NSW[\*\*\*](#cti21103-note-0015){ref-type="fn"}   |
+--------------------------------------------------------------------------+-------------------+-------------------+-------------------+-------------------+---------------------------------------------------------+
| Sum of GP‐spIgE (kU L^−1^)[\[Link\]](#cti21103-note-0011){ref-type="fn"} | 29.38 (8.0--70.3) | 20.69 (3.1--51.6) | 9.63 (2.5--24.3)  | 22.92 (7.4--88.0) | QLD \> NSW[\*](#cti21103-note-0013){ref-type="fn"}      |
|                                                                          |                   |                   |                   |                   |                                                         |
|                                                                          |                   |                   |                   |                   | SA \> NSW[\*](#cti21103-note-0013){ref-type="fn"}       |
+--------------------------------------------------------------------------+-------------------+-------------------+-------------------+-------------------+---------------------------------------------------------+

Data shown as median (interquartile range).

n.s., not significant; NSW, New South Wales; QLD, Queensland; SA, South Australia; SPT, skin prick test; WA, Western Australia.

Kruskal--Wallis test for difference between medians in groups with Dunn\'s pairwise comparisons.

Fisher\'s exact test for difference in frequencies.

*P* ≤ 0.05.

*P* ≤ 0.01.

*P* ≤ 0.001.

*P* ≤ 0.0001.

John Wiley & Sons, Ltd

The patterns of sensitisation to four common allergic GP amongst GP‐allergic participants from each state were compared within each region (Figure [1](#cti21103-fig-0001){ref-type="fig"}). GP‐allergic participants from QLD showed significantly higher levels of sensitisation to pollen of *P. notatum* and *C. dactylon* than *L. perenne* by SPT and serum spIgE (Figure [1](#cti21103-fig-0001){ref-type="fig"}a and b). QLD participants also showed higher serum spIgE with group 1 allergen components Pas n 1 (*P* ≤ 0.0001) and Cyn d 1 (*P* ≤ 0.01) than with Lol p 1 (Figure [1](#cti21103-fig-0001){ref-type="fig"}c).

![Levels of allergic sensitivity for patients with allergic rhinitis to four grass pollen extracts in different regions measured by skin prick test diameters \[**(a)** QLD *n* = 127--130; **(d)** WA *n* = 48; **(g)** NSW *n* = 18--21; **(j)** SA *n* = 69--72\], serum‐specific IgE concentrations to grass pollen extract \[**(b)** QLD *n* = 98; **(e)** WA *n* = 27; **(h)** NSW *n* = 26; **(k)** SA *n* = 34\] and serum‐specific IgE concentrations to purified group 1 allergen components \[**(c)** QLD *n* = 76 or 77; **(f)** WA *n* = 15--18; **(i)** NSW *n* = 14--23; **(l)** SA *n* = 28--31\]. \**P* ≤ 0.05, \*\**P* ≤ 0.01, \*\*\**P* ≤ 0.001 and \*\*\*\**P* ≤ 0.0001.](CTI2-9-e01103-g001){#cti21103-fig-0001}

In Western Australia (WA), GP‐allergic participants showed a higher level of sensitisation *L. perenne* GP than *S. halepense* GP by SPT diameter (*P* ≤ 0.05; Figure [1](#cti21103-fig-0001){ref-type="fig"}d) and serum spIgE (*P* ≤ 0.0001; Figure [1](#cti21103-fig-0001){ref-type="fig"}e). *L. perenne* GP‐spIgE concentrations were significantly higher than *C. dactylon* GP‐spIgE (*P* ≤ 0.0001), but no difference was observed in SPT (Figure [1](#cti21103-fig-0001){ref-type="fig"}d and e). The serum Lol p 1 spIgE concentrations were significantly higher than spIgE with Cyn d 1 (*P* ≤ 0.01), Sor h 1 (*P* ≤ 0.001) and Pas n 1 (*P* ≤ 0.01; Figure [1](#cti21103-fig-0001){ref-type="fig"}f).

In New South Wales (NSW), GP‐allergic participants showed a higher level of sensitisation to *L. perenne* than both *S. halepense* (*P* ≤ 0.01) and *C. dactylon* (*P* ≤ 0.001) by SPT (Figure [1](#cti21103-fig-0001){ref-type="fig"}g). This was more marked for serum spIgE concentrations to these GP extracts (*P* ≤ 0.0001; Figure [1](#cti21103-fig-0001){ref-type="fig"}h). The serum spIgE concentrations were significantly higher for Lol p 1 than any of the subtropical GP allergen, Cyn d 1 (*P* ≤ 0.001), Sor h 1 (*P* ≤ 0.01) and Pas n 1 (*P* ≤ 0.01; Figure [1](#cti21103-fig-0001){ref-type="fig"}i).

In South Australia (SA), GP‐allergic participants showed higher SPT diameters to *L. perenne* than to either *S. halepense* (*P* ≤ 0.01) or *C. dactylon* (*P* ≤ 0.001) and higher serum spIgE concentrations to the extracts (*P* ≤ 0.0001; Figure [1](#cti21103-fig-0001){ref-type="fig"}j and k). GP‐allergic participants from SA showed significantly higher concentrations of spIgE to Lol p 1 than any of the subtropical GP allergen, Cyn d 1 (*P* ≤ 0.001), Sor h 1 (*P* ≤ 0.0001) and Pas n 1 (*P* ≤ 0.0001; Figure [1](#cti21103-fig-0001){ref-type="fig"}l).

Cross‐inhibition of sIgE to purified allergen by GP extracts {#cti21103-sec-0007}
------------------------------------------------------------

Individual sera were subjected to microscale spIgE cross‐inhibition assays to examine further the specificity and avidity of IgE binding to purified pollen allergens of subtropical, Pas n 1 and Cyn d 1, as well as temperate, Lol p 1. The ages, gender, total IgE and sum of GP‐spIgE were similar amongst the subset of participants who were selected for spIgE cross‐inhibition assays for each region (Supplementary table [1](#cti21103-sup-0001){ref-type="supplementary-material"}). Differences were observed in Cyn d 1 spIgE levels in patient sera from QLD with NSW and SA (*P* \> 0.05). Exemplary inhibition curves for one patient from QLD and one patient from SA for inhibition of spIgE reactivity with Pas n 1, Cyn d 1 and Lol p 1 by subtropical Panicoideae: *P. notatum, S. halepense*; Chloridoideae: *C. dactylon*; and Pooideae: *L. perenne* and *P. pratense* GP extracts in comparison with raw peanut extract (RPN) are shown in Supplementary figures [3](#cti21103-sup-0001){ref-type="supplementary-material"}b, c and d, and [4](#cti21103-sup-0001){ref-type="supplementary-material"}b, c and d.

In QLD, self‐inhibition by the GP extract from which the allergen was purified was significantly higher than the RPN control for Pas n 1, Cyn d 1 and Lol p 1 (Figures [2](#cti21103-fig-0002){ref-type="fig"}a, b and c, and [3](#cti21103-fig-0003){ref-type="fig"}a, b and c). Maximum inhibition of spIgE reactivity with Pas n 1 by *C. dactylon* (*P* ≤ 0.05) and *L. perenne* GP (*P* ≤ 0.05) was significantly lower than self‐inhibition by *P. notatum* GP (Figure [2](#cti21103-fig-0002){ref-type="fig"}a). The area under the curve for spIgE of reactivity with Pas n 1 was significantly different than self‐inhibition by *P. notatum* GP, and *L. perenne* (*P* ≤ 0.01), *P. pratense* (*P* ≤ 0.001), *C. dactylon* (*P* ≤ 0.01) GP, but not *S. halepense* GP, indicating specific and avid IgE binding to Pas n 1 (Figure [3](#cti21103-fig-0003){ref-type="fig"}a). Maximum inhibition of spIgE reactivity with Cyn d 1 by *L. perenne* (*P* ≤ 0.001) and *P. pratense* (*P* ≤ 0.01) GP was significantly lower than self‐inhibition by *C. dactylon* GP (Figure [2](#cti21103-fig-0002){ref-type="fig"}b). Similarly, the area under the inhibition curves for spIgE reactivity with Cyn d 1 was significant different than self‐inhibition by *C. dactylon* GP for *L. perenne* (*P* ≤ 0.01) and *P. pratense* (*P* ≤ 0.01), indicating specific and avid IgE reactivity with Cyn d 1 (Figure [3](#cti21103-fig-0003){ref-type="fig"}b). Maximum inhibition of spIgE reactivity with Lol p 1 by *C. dactylon* was significantly lower (*P* ≤ 0.05) than self‐inhibition by *L. perenne* GP (Figure [2](#cti21103-fig-0002){ref-type="fig"}c). However, no difference in the area under the inhibition curve of spIgE reactivity to Lol p 1 was observed for any GP (*P* ≤ 0.0001; Figure [3](#cti21103-fig-0003){ref-type="fig"}c).

![Maximum cross‐inhibition of serum IgE reactivity with purified allergen components Pas n 1, Cyn d 1 and Lol p 1 by inhibitor extracts; *P. notatum* (![](CTI2-9-e01103-g004.jpg "image")), *S. halepense* (![](CTI2-9-e01103-g005.jpg "image")), *C. dactylon* (![](CTI2-9-e01103-g006.jpg "image")), *L. perenne* (![](CTI2-9-e01103-g007.jpg "image")), *P. pratense* (![](CTI2-9-e01103-g008.jpg "image")) and raw peanut control (![](CTI2-9-e01103-g009.jpg "image")) for a subset of patients from Queensland (QLD), Western Australia (WA), New South Wales (NSW) and South Australia (SA). Maximum inhibition expressed as median and interquartile range. \**P* ≤ 0.05, \*\**P* ≤ 0.01, \*\*\**P* ≤ 0.001 and \*\*\*\**P* ≤ 0.0001.](CTI2-9-e01103-g002){#cti21103-fig-0002}

![Difference in area under the cross‐inhibition curve between inhibition of specific IgE reactivity with purified allergen components Pas n 1, Cyn d 1 and Lol p 1 by inhibitor extracts; *P. notatum*, *S. halepense*, *C. dactylon*, *L. perenne*, *P. pratense* and raw peanut negative control, for a subset of patients in Queensland (QLD), Western Australia (WA), New South Wales (NSW) and South Australia (SA). Data expressed as median and upper quartile (whiskers) difference in area under the curve (AUC) relative to the self‐inhibitor grass pollen (GP) extract and other inhibitor extracts. \**P* ≤ 0.05, \*\**P* ≤ 0.01, \*\*\**P* ≤ 0.001 and \*\*\*\**P* ≤ 0.0001.](CTI2-9-e01103-g003){#cti21103-fig-0003}

In WA, significant self‐inhibition was observed for Pas n 1 (*P* ≤ 0.0001), Cyn d 1 (*P* ≤ 0.01) and Lol p 1 (*P* ≤ 0.0001) (Figures [2](#cti21103-fig-0002){ref-type="fig"}d, e and f, and [3](#cti21103-fig-0003){ref-type="fig"}d, e and f). spIgE reactivity with Pas n 1 by *C. dactylon* (*P* ≤ 0.001) was significantly lower than self‐inhibition by *P. notatum* by maximum inhibition and area under the inhibition curve, exemplifying the difference in IgE specificity between Cyn d 1 and Pas n 1 (Figures [2](#cti21103-fig-0002){ref-type="fig"}d and [3](#cti21103-fig-0003){ref-type="fig"}d). No significant difference in the area under the inhibition curve of IgE reactivity with Cyn d 1 between self‐inhibition by *C. dactylon* and other GP was observed (Figure [3](#cti21103-fig-0003){ref-type="fig"}e). Maximum inhibition of spIgE reactivity with Lol p 1 by *C. dactylon* was significantly lower (*P* ≤ 0.0001) than self‐inhibition by *L. perenne* GP (Figure [2](#cti21103-fig-0002){ref-type="fig"}f). Large differences in the area under the inhibition curves of spIgE reactivity to Lol p 1 between self‐inhibition by *L. perenne* and *C. dactylon* (*P* ≤ 0.0001) and *S. halepense* (*P* ≤ 0.05) were observed (Figure [3](#cti21103-fig-0003){ref-type="fig"}f).

In NSW, self‐inhibition compared with RPN was observed for Pas n 1 (*P* ≤ 0.01), Cyn d 1 (*P* ≤ 0.001) and Lol p 1 (*P* ≤ 0.001) based on maximum inhibition (Figure [2](#cti21103-fig-0002){ref-type="fig"}g, h and i) and for Pas n 1 (*P* ≤ 0.0001) and Lol p 1(*P* ≤ 0.0001) by difference in the area under the inhibition curve (Figure [3](#cti21103-fig-0003){ref-type="fig"}g and i). However, the area under the curve between self‐inhibition of Cyn d 1 spIgE by *C. dactylon* GP did not differ from RPN indicating that IgE binding to Cyn d 1 in these subjects may not have been specific for Cyn d 1 (Figure [3](#cti21103-fig-0003){ref-type="fig"}h). spIgE reactivity to Pas n 1 was inhibited less by *C. dactylon* GP than *P. notatum* GP based on the area under the inhibition curve (*P* ≤ 0.001) but the maximum inhibition did not differ (Figures [2](#cti21103-fig-0002){ref-type="fig"}g and [3](#cti21103-fig-0003){ref-type="fig"}g). spIgE reactivity with Lol p 1 was inhibited less by *C. dactylon* GP than self‐inhibition by *L. perenne* based on maximum inhibition (*P* ≤ 0.0001) and difference in area under the inhibition curve (*P* \< 0.001; Figures [2](#cti21103-fig-0002){ref-type="fig"}i and [3](#cti21103-fig-0003){ref-type="fig"}i).

In SA, significant self‐inhibition compared to RPN was observed for spIgE reactivity with Pas n 1 (*P* \< 0.0001) and Lol p 1 (*P* ≤ 0.0001 (Figures [2](#cti21103-fig-0002){ref-type="fig"}j, k and l, and [3](#cti21103-fig-0003){ref-type="fig"}j, k and l). Inhibition of Pas n 1 spIgE reactivity by *C. dactylon* GP was significantly lower than self‐inhibition by *P. notatum* GP by maximum inhibition (*P* ≤ 0.0001) and difference in area under the inhibition curve (*P* ≤ 0.0001; Figures [2](#cti21103-fig-0002){ref-type="fig"}j and [3](#cti21103-fig-0003){ref-type="fig"}j). The maximum inhibition of spIgE reactivity of Cyn d 1 by RPN did not differ (Figure [2](#cti21103-fig-0002){ref-type="fig"}k), but significant differences from self‐inhibition by *C. dactylon* GP based on area under the inhibition curve were observed with *P. notatum* GP (*P* ≤ 0.001), *L. perenne* GP (*P* ≤ 0.0001) and *P. pratense* GP (*P* ≤ 0.001; Figure [3](#cti21103-fig-0003){ref-type="fig"}k). Maximum inhibition of Lol p 1 spIgE reactivity by *C. dactylon* GP (*P*\<0.0001), *S. halepense* (*P*\<0.0001) and *P. notatum* (*P*\<0.01) were significantly lower than self‐inhibition by *L. perenne* GP (Figure [2](#cti21103-fig-0002){ref-type="fig"}l). The area under the inhibition curve of spIgE reactivity with Lol p 1 was lower than self‐inhibition by *L. perenne* GP for *C. dactylon* GP (*P* ≤ 0.0001), *P. notatum* GP (*P* ≤ 0.01) and *S. halepense* GP (*P* ≤ 0.001), whilst that for *P. pratense* GP was similar to *L. perenne* GP (Figure [3](#cti21103-fig-0003){ref-type="fig"}l).

Discussion {#cti21103-sec-0008}
==========

Whilst GP is the major outdoor allergen trigger for allergic rhinitis worldwide, there is considerable biological diversity amongst Poaceae subfamilies that influences the allergen composition and degree of similarity between GP allergens.[8](#cti21103-bib-0008){ref-type="ref"}, [22](#cti21103-bib-0022){ref-type="ref"} Biogeographical variation over four regions in Australia with different latitudes and climates, QLD, WA, NSW and SA, appeared to affect the level of sensitisation to Panicoideae, Chloridoideae and Pooideae GP determined by skin prick test diameter as well as serum spIgE concentration to GP extracts and purified group 1 allergen components. Overall, participants from the subtropical region of QLD showed higher sensitivity to Panicoideae and Chloridoideae GP, whilst those from temperate climates of SA showed higher sensitivity to the Pooideae GP.

The observed difference in concentrations of spIgE to GP allergen components appeared to be more pronounced than differences between concentrations of spIgE to whole GP extracts, for example spIgE to Lol p 1 compared to *L. perenne* GP extract in WA, NSW and SA, suggesting that measuring spIgE to allergen components may offer better diagnostic precision than GP extracts.[22](#cti21103-bib-0022){ref-type="ref"} However, diagnostic tests for spIgE to Pas n 1 and Sor h 1 are not available commercially and Cyn d 1 is only available as a natural purified allergen component, which may show false positives because of cross‐reactive carbohydrate determinants (CCD) in populations where grass is not an important aeroallergen source.

This study is one of the first to compare GP allergen sensitisation profiles from multiple states across a wide geographical range separated by 4300 km east to west and 1100 km north to south. The IgE cross‐inhibition assays revealed regional variation in the avidity of spIgE for purified group 1 allergen components subtropical and temperate GP. Specific and unique recognition of Pas n 1 and Cyn d 1 by participant spIgE was observed for individuals from the subtropical region of QLD that could not be blocked by *L. perenne* or *P. pratense* GP. Conversely, in the temperate region of SA, spIgE reactivity with Lol p 1 was inhibited less by Panicoideae and Chloridoideae GP.

The use of microscale cross‐inhibition assays allowed for resolution of specificity and avidity of spIgE reactivity for the three group 1 allergens by comparing both maximum inhibition and the area under the inhibition curve comparisons for GP from separate subfamilies. The comparisons of difference in the area under the inhibition curves between other GP and self‐inhibitor GP extracts indicated differences in spIgE avidity. In previous studies, investigators have compared the inhibitor concentration at which 50% inhibition (IC50) is reached.[18](#cti21103-bib-0018){ref-type="ref"} In this study, cases where GP extracts and the irrelevant plant inhibitor control RPN extract did not reach the IC50, the area under the curve was more useful than reliance on IC50 for quantitative analysis. For example, in patients from QLD, only *C. dactylon* and *L. perenne* showed significantly different maximum inhibition to *P. notatum* self‐inhibition of spIgE to Pas n 1, whereas analysis of the area under inhibition curves revealed differences between *C. dactylon*, *L. perenne* and *P. pratense* GP and *P. notatum* GP. Similarly, for participants from WA, only *C. dactylon* GP showed a significant difference in maximum inhibition of spIgE with Lol p 1, whereas analysis of area under the curve indicated significant differences from self‐inhibition of spIgE with Lol p 1 by *L. perenne* GP and *C. dactylon* as well as *S. halepense* GP.

Across all regions, GP from the same subfamily showed comparable IgE reactivity to each other, as exemplified by the Panicoideae *P. notatum* and *S. halepense* and Pooideae *L. perenne* and *P. pratense* GP. *C. dactylon* GP showed unique spIgE reactivity indicating the presence of some distinct Cyn d 1 epitopes compared to allergens of either Panicoideae or Pooideae GP. The phylogenetic relationship between grasses within subfamilies is closer than between subfamilies,[16](#cti21103-bib-0016){ref-type="ref"} and consequently, there is higher primary sequence similarities of major allergens within subfamilies.[23](#cti21103-bib-0023){ref-type="ref"} Structural differences between epitopes of allergens of separate grass subfamilies are likely to account for the observed region‐dependent, species‐specific IgE recognition of GP allergens in sensitised GP‐allergic participants, although there has been little comparative B‐cell epitope analysis of GP allergens to date.[15](#cti21103-bib-0015){ref-type="ref"}, [24](#cti21103-bib-0024){ref-type="ref"}

A limitation of this study was the small number of NSW participants, reducing the sample size for the cross‐inhibition analysis (*n* = 8), because of low serum availability. Also, of the 15 participants living in QLD who were selected for the cross‐inhibition assays based on sum of GP‐specific IgE and serum availability, four were born outside QLD, in regions with a predominance of *L. perenne* (i.e. NSW, WA and the United Kingdom), contributing to variation in the range of inhibition of spIgE with Pas n 1 and Lol p 1 by *L. perenne* and *P. pratense* GP. This suggests the place of origin where sensitisation occurred and migration, may diversify the allergen sensitisation profiles of individuals within a population. Regional differences in sensitisation rates, even for closely related taxa, based on analysis of large Japanese IgE data sets have been recently reported.[25](#cti21103-bib-0025){ref-type="ref"} These findings reinforce that clinical interpretation of spIgE responses needs to be correlated with symptoms upon exposure and the allergens likely to be encountered by the patient within their usual environment.

Allergen‐specific immunotherapy (AIT) offers effective reduction in symptoms and reduces new sensitisations and the risk of progression to asthma in children.[26](#cti21103-bib-0026){ref-type="ref"} Assessment of patients receiving temperate GP sublingual immunotherapy (SLIT) tablets showed lowered mean AR medication prescriptions and lower proportions of new onset of asthma than the non‐AIT‐treated groups.[27](#cti21103-bib-0027){ref-type="ref"} However, currently available AIT is not standardised for subtropical GP, which may be important for efficacious treatment of people who are primarily allergic to Panicoideae and/or Chloridoideae GP, given that only one of three T‐cell epitopes is shared between major allergens Pas n 1, Cyn d 1 and Lol p 1.[28](#cti21103-bib-0028){ref-type="ref"}, [29](#cti21103-bib-0029){ref-type="ref"}, [30](#cti21103-bib-0030){ref-type="ref"} More specific assessment of GP sensitisation profiles, particularly in countries with multiple climatic zones, may serve to precisely identify the relevant GP to achieve the most efficacious treatment for an individual patient.[22](#cti21103-bib-0022){ref-type="ref"} More broadly, understanding current patterns of allergic sensitisation is important for being prepared to respond to changing floristic zones and allergen distributions in future.

Conclusions {#cti21103-sec-0009}
===========

The outcomes of this study demonstrate that sensitisation to GP in AR patients varies according to the biogeographical region of residence. Patients showed more specific and avid IgE reactivity to GP of the most biogeographically abundant grasses within their respective climatic regions. GP of the same subfamily showed similar levels of spIgE cross‐inhibition to each other indicating subfamily‐specific allergic sensitisation. Allergens of the two subtropical Panicoideae and Chloridoideae grass subfamilies show separate IgE reactivity patterns. Regional variation in allergic sensitivity is clinically important worldwide for optimal diagnosis and targeted AIT for patients with AR because of GP allergy, especially in places where patients may be co‐exposed to multiple types of GP from separate subfamilies.

Methods {#cti21103-sec-0010}
=======

Participants {#cti21103-sec-0011}
------------

Participants for the Grass Pollen Allergy Study (GPAS; HREC/2009/QPAH/296)[20](#cti21103-bib-0020){ref-type="ref"} were recruited with informed consent. Adult participants \[NA *n* = 29, OA *n* = 54\] and GP‐allergic participants with AR (*n* = 330) were recruited at clinical allergy and immunology specialist clinics in QLD: Cairns, Townsville, Brisbane, Toowoomba and the Gold Coast (latitudes −21 to −27°S); Western Australia (WA): Perth and Fremantle (latitude −32°S); New South Wales (NSW): Sydney (latitude −33.9°S); and South Australia (SA): Adelaide (latitude −35°S) (Table [1](#cti21103-tbl-0001){ref-type="table"}). Patients who had prior GP immunotherapy were excluded. Participant demographics, clinical history and SPT to ten environmental aeroallergen extracts including four GP, *P. notatum, S. halepense*, *C. dactylon* and *L. perenne*, Southern GP mix (*Poa pratensis, Dactylis glomerata, Agrostis gigantea, Phleum pratense, Anthoxanthum odoratum*), as well as house dust mite, cat dander, *Alternaria, Aspergillus* moulds and ragweed pollen (GreerLabs, Lenoir, NC, USA), were assessed.[20](#cti21103-bib-0020){ref-type="ref"} Serum total and spIgE to four GP extracts (g17, g10, g2 and g5 ImmunoCAPs, Thermo Fisher Scientific, Uppsala, Sweden) were measured. spIgE concentrations to purified natural allergen components, Pas n 1, Cyn d 1 and Lol p 1, that were biotinylated were measured using streptavidin ImmunoCAPs as previously described.[20](#cti21103-bib-0020){ref-type="ref"}

Cross‐inhibition assay by DELFIA time‐resolved fluorescence {#cti21103-sec-0012}
-----------------------------------------------------------

A subset of sera from 8 to 15 GP‐allergic participants were selected from each region based on availability of serum and sum of spIgE concentrations to four GP. Individual sera were firstly titrated against three purified allergens representing each of the Poaceae subfamilies, Pas n 1, Cyn d 1 and Lol p 1, coated at 1 μg mL^−1^,[20](#cti21103-bib-0020){ref-type="ref"} from a serum dilution of 1/10 with fourfold serial dilutions (exemplified in Supplementary figures [2](#cti21103-sup-0001){ref-type="supplementary-material"} and [3](#cti21103-sup-0001){ref-type="supplementary-material"}). The mid‐point of the linear phase of the titration curve was chosen for each individual as the serum dilution for the cross‐inhibition assay. For each serum, the same dilution was used for testing inhibition of spIgE with for each of the three allergens. Cross‐inhibition immunoassays of spIgE reactivity with Pas n 1, Cyn d 1 and Lol p 1 were then performed as previously described[17](#cti21103-bib-0017){ref-type="ref"} with the following modifications. Five GP extracts, and RPN extract as an irrelevant plant allergen control, were tested as inhibitors at concentrations of 0.016--100 μg mL^−1^. Assays were performed in quadruplicate in a 10 μL volume in 384‐well format assisted by semi‐automated liquid handling. Allergen spIgE binding was assessed by incubation with polyclonal rabbit anti‐human IgE (Dako, Glostrup, Denmark) at 1/2000 dilution and then Europium‐conjugated goat anti‐rabbit IgG (PerkinElmer, Waltham, MA, USA) at 1/1000 dilution. Reactivity was detected by DELFIA Time‐Resolved Fluorescence (PerkinElmer) after 20‐min incubation at room temperature.

Data analysis {#cti21103-sec-0013}
-------------

Participant gender and percentage with asthma were assessed by Fisher\'s exact test for difference in frequencies between groups. Outcomes of continuous variables were tested for normality of distribution by the Kolmogorov--Smirnov test. Participant age, sum of SPT and total IgE between groups were then compared by Kruskal--Wallis ANOVA for difference between medians in groups with Dunn\'s pairwise comparisons.

Responses of GP‐allergic participants within each state for SPT, serum spIgE to GP extracts and purified group 1 allergen components were expressed as scatterplots with median and interquartile range. Data were compared by Friedman ANOVA with Dunn\'s multiple comparison for paired data of participants within each state.

For spIgE cross‐inhibition data, the maximum inhibition and area under the curve were calculated. Self‐inhibition was defined as inhibition of IgE reactivity with a purified allergen by the GP extract the allergen was derived from, such as the inhibition of Pas n 1 spIgE reactivity by *P. notatum* GP, Cyn d 1 by *C. dactylon* GP and Lol p 1 by *L. perenne* GP. Significant self‐inhibition was judged to have been achieved when self‐inhibition is significantly higher than the inhibition of spIgE reactivity by the irrelevant plant allergen inhibition control of RPN extract. The differences between the maximum level of self‐inhibition and maximum level of inhibition by the other GP extracts were compared. The difference in area under the inhibition curve for each inhibitor extract relative to self‐inhibition was calculated by subtraction from the area under the curve for the self‐inhibitor extract. Area under the curve data were expressed as graph bars of the median difference in area under the curve with upper interquartile range as upper whisker.
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